Comparative Pharmacology
Head-to-head clinical analysis: KYLEENA versus NEXPLANON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KYLEENA versus NEXPLANON.
KYLEENA vs NEXPLANON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that suppresses endometrial proliferation, thickens cervical mucus, and induces endometrial atrophy. It also partially inhibits ovulation.
Progestin-only contraceptive that suppresses ovulation primarily by inhibiting the mid-cycle LH surge. It also thickens cervical mucus, impeding sperm penetration, and alters endometrial lining.
KYLEENA (levonorgestrel-releasing intrauterine system 19.5 mg) is inserted into the uterine cavity by a healthcare professional. One system releases levonorgestrel at approximately 17.5 mcg/day initially, decreasing to 7.4 mcg/day after 1 year and 5.1 mcg/day after 3 years, and is effective for up to 5 years.
68 mg subdermal implant inserted in the inner upper arm; provides contraception for up to 3 years.
None Documented
None Documented
Terminal elimination half-life is approximately 25 hours (range 18–30 hours) after repeated dosing; supports once-daily dosing but not applicable for IUD as systemic absorption is minimal.
Terminal elimination half-life approximately 25 hours (range 20-30 hours) after removal; steady-state achieved within 3-4 days; clinical effect persists for 3-4 weeks post-removal due to residual subcutaneous depot.
Renal (fecal negligible). Levonorgestrel is extensively metabolized; metabolites are excreted primarily in urine (40–68%) and to a lesser extent in feces (16–48%).
Renal (40-50% as metabolites), fecal (30-40% as metabolites), with <1% unchanged in urine; enterohepatic circulation contributes to prolonged elimination.
Category C
Category C
Contraceptive
Contraceptive